Ascletis Pharma (HKG:1672) showed positive topline results in its phase 1B trial for its ASC47 anti-obesity drug in Australia, according to a Wednesday filing with the Hong Kong bourse.
The trial found ASC47 safe and well-tolerated in patients with low-density lipoprotein cholesterol and obesity, the filing said.
Meanwhile, the US Food and Drug Administration also cleared ASC47's combination with semaglutide for obesity, the filing said.
Shares rose 6% during Wednesday's late morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.